Background: Administration of cyproterone acetate (CPA), to reduce the production and effects of testosterone, is often part of clinical regimens for trans individuals seeking feminization. Due to the potency of CPA, there are dose-related side effects and over-suppression of testosterone that can occur.
No takes yet. Share an insight, caveat, or question.
Warzywoda et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: